MIST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MIST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Milestone Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 10.11.
Milestone Pharmaceuticals has a quick ratio of 10.11. It generally indicates good short-term financial strength.
The historical rank and industry rank for Milestone Pharmaceuticals's Quick Ratio or its related term are showing as below:
During the past 7 years, Milestone Pharmaceuticals's highest Quick Ratio was 24.14. The lowest was 10.11. And the median was 17.17.
The historical data trend for Milestone Pharmaceuticals's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Quick Ratio | Get a 7-Day Free Trial | 14.71 | 24.14 | 17.55 | 11.70 | 10.11 |
Milestone Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Quick Ratio | Get a 7-Day Free Trial | 11.70 | 13.63 | 13.89 | 10.45 | 10.11 |
For the Biotechnology subindustry, Milestone Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Milestone Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Quick Ratio (A: Dec. 2023 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (73.032 | - | 0) | / | 7.226 | |
= | 10.11 |
Milestone Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as
Quick Ratio (Q: Dec. 2023 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (73.032 | - | 0) | / | 7.226 | |
= | 10.11 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals (NAS:MIST) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Milestone Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
David Bharucha | officer: Chief Medical Officer | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
Debra K. Liebert | director | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
Richard C Pasternak | director | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6 |
Michael John Tomsicek | director | 28 OVERLOOK DRIVE, BEDFORD MA 01730 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
Roderick Wong | 10 percent owner | C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Jeffrey Edward Nelson | officer: Chief Operating Officer | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
Paul F Truex | director | PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Lisa M. Giles | director | DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606 |
Fonds De Solidarite Des Travailleurs Du Quebec | 10 percent owner | 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
Novo Holdings A/s | 10 percent owner, other: SEE REMARKS | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Amit Hasija | officer: CFO & EVP of Corp. Development | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6 |
Lorenz Muller | officer: Chief Commercial Officer | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
From GuruFocus
By Business Wire • 12-26-2023
By PRNewswire PRNewswire • 06-20-2023
By PRNewswire PRNewswire • 04-12-2023
By PRNewswire • 10-24-2023
By PRNewswire PRNewswire • 06-01-2023
By PRNewswire PRNewswire • 10-25-2022
By PRNewswire PRNewswire • 02-28-2023
By PRNewswire • 01-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.